Moreover, Karachi group experiments demonstrated that the use of temozolomide at standard therapeutic doses in a mouse glioblastoma model resulted in increased expression of PD-L1 on CD4+, CD8+ T cells and T regulatory cells, as well as increased expression of other cellular depletion markers LAG-3 and TIM-3 [49]. Here, CD4 is linked to glioblastoma.